Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
22 avr. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN...
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
16 avr. 2024 07h30 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
13 mars 2024 16h22 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
11 mars 2024 07h42 HE
|
Lexeo Therapeutics
Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...
Lexeo Therapeutics Announces Oversubscribed $95.0 Million Equity Financing
11 mars 2024 07h30 HE
|
Lexeo Therapeutics
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined...
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
05 févr. 2024 07h00 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Strengthens Clinical Development Leadership with New Executive Appointments
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
LEXEO Therapeutics
Lexeo Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic Cardiomyopathy (ACM)
18 déc. 2023 07h00 HE
|
LEXEO Therapeutics
Lexeo Therapeutics Granted FDA Fast Track Designation and Orphan Drug Designation for LX2020, an AAV-Based Gene Therapy Candidate for PKP2 Arrhythmogenic
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
11 déc. 2023 07h00 HE
|
LEXEO Therapeutics
Lexeo Therapeutics Reports Third Quarter 2023 Financial Results and Operational Highlights
Lexeo Therapeutics Announces Pricing of Initial Public Offering
02 nov. 2023 21h51 HE
|
LEXEO Therapeutics
NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to...